Adents launches blockchain-powered Verification Router Service for pharma makers

Adents is launching a Verification Router Service for pharmaceutical manufactuers and disburtors powered by a new blockchain technology platform.

Developed in collaboration with Microsoft, the blockchain-based Adents NovaTrack has led to the introduction of a seamless Adents Verification Router Service Solution per upcoming US pharmaceuticals serialisation requirements.

A Verification Router Service – or VRS – is one of a series of milestone requirements that will come into play during the next phase of the Drug Supply Chain Security Act.

Beginning in late November 2019, no returned serialised product may be resold until the wholesale distributor verifies that product’s unique identifiers, including the SNI for each sealed homogeneous case or package.

A VRS is an interoperable solution used to manage the acceptance, formatting and delivery of requests and responses to support these DSCSA verification requirements, as well as other business requirements defined between trading partners.

Some 60 million pharmaceutical saleable product returns occur each year in the US market. This year, the establishment of shared standards for sales stream reintegration has become vital for the pharmaceutical industry.

Essentially, a VRS allows companies to verify products by entering the four product identifier elements – GTIN, serial number, lot and expiry – into a request, which is then forwarded, via the lookup directory, to the appropriate manufacturer repository.

Next, a response is generated from the manufacturer’s repository and routed back to the requestor, detailing whether the product is verified — and whether it can be returned to saleable inventory.

It is against this landscape that, through Adents NovaTrack, the new Adents VRS Solution will excel, not only due to its Blockchain-based functionality but also differentiators within this Blockchain niche.

First and foremost, unlike competing Blockchain-based solutions, Adents NovaTrack is entirely agnostic, making it compatible with any Level 4 (enterprise level) serialisation solution.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Related news

Emergent joins partnership for COVID-19 vaccine development & manufacturing

Emergent BioSolutions has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to deploy its...

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...